Addex Therapeutics (ADXN) EBIAT (2018 - 2025)
Addex Therapeutics' EBIAT history spans 8 years, with the latest figure at -$2.2 million for Q4 2025.
- On a quarterly basis, EBIAT rose 61.61% to -$2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.1 million, a 100.0% increase, with the full-year FY2025 number at -$8.1 million, down 44.81% from a year prior.
- EBIAT came in at -$2.2 million for Q4 2025, down from -$2.0 million in the prior quarter.
- The five-year high for EBIAT was -$579883.9 in Q2 2023, with the low at -$3536.9 billion in Q1 2024.
- Historically, EBIAT has averaged -$176.8 billion across 5 years, with a median of -$2.9 million in 2021.
- Biggest five-year swings in EBIAT: tumbled 135900948.17% in 2024 and later surged 100.0% in 2025.
- Year by year, EBIAT stood at -$16.6 million in 2021, then decreased by 29.71% to -$21.6 million in 2022, then skyrocketed by 86.95% to -$2.8 million in 2023, then plummeted by 98.83% to -$5.6 million in 2024, then skyrocketed by 61.61% to -$2.2 million in 2025.
- Business Quant data shows EBIAT for ADXN at -$2.2 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.4 million in Q2 2025.